News from precigen, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 06, 2023, 16:05 ET Precigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

– Achieved significant clinical progress for UltraCAR-T® and AdenoVerse™ investigational therapeutics in 2022 – – Presented positive clinical data...

Jan 27, 2023, 16:05 ET Precigen Announces Closing of Public Offering of Common Stock

Precigen, Inc. (Nasdaq: PGEN) announced today the closing of its previously announced underwritten public offering of common stock. Precigen sold...

Jan 24, 2023, 22:40 ET Precigen Announces Pricing of $75.0 Million Public Offering of Common Stock

Precigen, Inc. (Nasdaq: PGEN) today announced the pricing of an underwritten public offering of 42,857,143 shares of its common stock at a public...

Jan 24, 2023, 16:05 ET Precigen Announces Proposed $75.0 Million Public Offering of Common Stock

Precigen, Inc. (Nasdaq: PGEN) today announced it has commenced an underwritten public offering of $75.0 million of its common stock. In addition,...

Jan 24, 2023, 16:01 ET Precigen Announces Positive Phase 1 Dose Escalation and Expansion Cohort Data for Investigational Off-the-Shelf PRGN-2012 AdenoVerse™ Immunotherapy in Patients with Recurrent Respiratory Papillomatosis

– Repeated administrations of PRGN-2012 were well-tolerated with no dose-limiting toxicities and no treatment-related adverse events greater than...

Jan 11, 2023, 18:45 ET Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...

Jan 04, 2023, 16:05 ET Precigen to Host a Virtual R&D Event on January 24th to Share Safety and Efficacy Data from the Phase 1 Dose Escalation and Expansion Cohorts of PRGN-2012 AdenoVerse™ Immunotherapy in Recurrent Respiratory Papillomatosis

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...

Dec 19, 2022, 16:05 ET Precigen to Present at the 41st Annual J.P. Morgan Healthcare Conference

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...

Dec 12, 2022, 19:01 ET Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients

– Single infusion of UltraCAR-T cells with or without lymphodepletion demonstrated robust expansion and persistence in blood and bone marrow – –...

Nov 09, 2022, 16:05 ET Precigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs

– Company will host virtual R&D event in early January 2023, timed to coincide with the 41st Annual JP Morgan Healthcare Conference, to showcase...

Nov 02, 2022, 16:30 ET Precigen to Announce Third Quarter 2022 Financial Results on November 9th

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...

Sep 21, 2022, 16:30 ET Precigen Names Rutul R. Shah Chief Operating Officer

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...

Sep 01, 2022, 08:05 ET Precigen to Participate in the 2022 Wells Fargo Healthcare Conference

Precigen, Inc. (NASDAQ: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...

Aug 22, 2022, 08:05 ET Precigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...

Aug 08, 2022, 16:05 ET Precigen Reports Second Quarter and First Half 2022 Financial Results

– Enrollment complete in Phase 1 study of PRGN-3006 UltraCAR-T® in acute myeloid leukemia (AML); enrollment ongoing in Phase 1b dose expansion study; ...

Aug 01, 2022, 16:05 ET Precigen to Announce Second Quarter and First Half 2022 Financial Results on August 8th

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...

Jul 05, 2022, 08:05 ET Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...

Jun 27, 2022, 16:05 ET Precigen to Participate in the Stifel 2022 Virtual Cell Therapy Summit

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...

May 17, 2022, 16:05 ET Precigen to Participate in the 2022 H.C. Wainwright Global Investment Conference

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...

May 09, 2022, 16:05 ET Precigen Reports First Quarter 2022 Financial Results and Business Updates

– Fast Track designation received for PRGN-3006 UltraCAR-T®, an important milestone for patients with relapsed or refractory acute myeloid leukemia,...

Apr 04, 2022, 08:05 ET Precigen Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...

Mar 01, 2022, 08:00 ET Precigen Reports Fourth Quarter and Full Year 2021 Financial Results

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...

Jan 12, 2022, 16:30 ET Precigen Provides Pipeline and Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...

Jan 05, 2022, 16:05 ET Precigen to Present at the 40th Annual J.P. Morgan Healthcare Conference

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...

Dec 13, 2021, 17:05 ET Precigen Announces Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T® in Relapsed or Refractory Acute Myeloid Leukemia

Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients,...